vs

Side-by-side financial comparison of CABOT CORP (CBT) and Invesco (IVZ). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $849.0M, roughly 2.0× CABOT CORP). CABOT CORP runs the higher net margin — 8.6% vs -58.9%, a 67.5% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs -11.1%). Invesco produced more free cash flow last quarter ($432.2M vs $57.0M). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs -8.7%).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

CBT vs IVZ — Head-to-Head

Bigger by revenue
IVZ
IVZ
2.0× larger
IVZ
$1.7B
$849.0M
CBT
Growing faster (revenue YoY)
IVZ
IVZ
+17.3% gap
IVZ
6.2%
-11.1%
CBT
Higher net margin
CBT
CBT
67.5% more per $
CBT
8.6%
-58.9%
IVZ
More free cash flow
IVZ
IVZ
$375.2M more FCF
IVZ
$432.2M
$57.0M
CBT
Faster 2-yr revenue CAGR
IVZ
IVZ
Annualised
IVZ
7.1%
-8.7%
CBT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBT
CBT
IVZ
IVZ
Revenue
$849.0M
$1.7B
Net Profit
$73.0M
$-995.9M
Gross Margin
24.9%
Operating Margin
15.2%
-86.2%
Net Margin
8.6%
-58.9%
Revenue YoY
-11.1%
6.2%
Net Profit YoY
-21.5%
-575.8%
EPS (diluted)
$1.37
$-2.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
IVZ
IVZ
Q4 25
$849.0M
$1.7B
Q3 25
$899.0M
$1.6B
Q2 25
$923.0M
$1.5B
Q1 25
$936.0M
$1.5B
Q4 24
$955.0M
$1.6B
Q3 24
$1.0B
$1.5B
Q2 24
$1.0B
$1.5B
Q1 24
$1.0B
$1.5B
Net Profit
CBT
CBT
IVZ
IVZ
Q4 25
$73.0M
$-995.9M
Q3 25
$43.0M
$356.4M
Q2 25
$101.0M
$197.4M
Q1 25
$94.0M
$171.1M
Q4 24
$93.0M
$209.3M
Q3 24
$137.0M
$55.0M
Q2 24
$109.0M
$132.2M
Q1 24
$84.0M
$141.5M
Gross Margin
CBT
CBT
IVZ
IVZ
Q4 25
24.9%
Q3 25
24.5%
Q2 25
26.4%
Q1 25
25.7%
Q4 24
24.6%
Q3 24
24.0%
Q2 24
25.2%
Q1 24
24.1%
Operating Margin
CBT
CBT
IVZ
IVZ
Q4 25
15.2%
-86.2%
Q3 25
15.2%
16.5%
Q2 25
18.1%
14.1%
Q1 25
17.3%
18.1%
Q4 24
16.2%
19.6%
Q3 24
15.0%
6.6%
Q2 24
16.9%
13.9%
Q1 24
15.3%
14.4%
Net Margin
CBT
CBT
IVZ
IVZ
Q4 25
8.6%
-58.9%
Q3 25
4.8%
21.7%
Q2 25
10.9%
13.0%
Q1 25
10.0%
11.2%
Q4 24
9.7%
13.1%
Q3 24
13.7%
3.6%
Q2 24
10.7%
8.9%
Q1 24
8.2%
9.6%
EPS (diluted)
CBT
CBT
IVZ
IVZ
Q4 25
$1.37
$-2.61
Q3 25
$0.80
$0.66
Q2 25
$1.86
$-0.03
Q1 25
$1.69
$0.38
Q4 24
$1.67
$0.46
Q3 24
$2.41
$0.12
Q2 24
$1.94
$0.29
Q1 24
$1.49
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
IVZ
IVZ
Cash + ST InvestmentsLiquidity on hand
$230.0M
$1.0B
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$1.6B
$12.2B
Total Assets
$3.8B
$27.1B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
IVZ
IVZ
Q4 25
$230.0M
$1.0B
Q3 25
$258.0M
$973.1M
Q2 25
$239.0M
$922.7M
Q1 25
$213.0M
$821.7M
Q4 24
$183.0M
$986.5M
Q3 24
$223.0M
$1.0B
Q2 24
$197.0M
$878.5M
Q1 24
$206.0M
$895.7M
Total Debt
CBT
CBT
IVZ
IVZ
Q4 25
$1.8B
Q3 25
$1.1B
$1.6B
Q2 25
$1.9B
Q1 25
$964.8M
Q4 24
$890.6M
Q3 24
$1.1B
$890.3M
Q2 24
$890.1M
Q1 24
$1.3B
Stockholders' Equity
CBT
CBT
IVZ
IVZ
Q4 25
$1.6B
$12.2B
Q3 25
$1.6B
$14.0B
Q2 25
$1.5B
$13.9B
Q1 25
$1.4B
$14.7B
Q4 24
$1.4B
$14.6B
Q3 24
$1.4B
$14.8B
Q2 24
$1.3B
$14.6B
Q1 24
$1.4B
$14.6B
Total Assets
CBT
CBT
IVZ
IVZ
Q4 25
$3.8B
$27.1B
Q3 25
$3.8B
$28.4B
Q2 25
$3.8B
$28.5B
Q1 25
$3.8B
$28.1B
Q4 24
$3.6B
$27.0B
Q3 24
$3.7B
$27.5B
Q2 24
$3.6B
$27.2B
Q1 24
$3.6B
$28.1B
Debt / Equity
CBT
CBT
IVZ
IVZ
Q4 25
0.15×
Q3 25
0.70×
0.12×
Q2 25
0.14×
Q1 25
0.07×
Q4 24
0.06×
Q3 24
0.75×
0.06×
Q2 24
0.06×
Q1 24
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
IVZ
IVZ
Operating Cash FlowLast quarter
$126.0M
$455.8M
Free Cash FlowOCF − Capex
$57.0M
$432.2M
FCF MarginFCF / Revenue
6.7%
25.5%
Capex IntensityCapex / Revenue
8.1%
1.4%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$401.0M
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
IVZ
IVZ
Q4 25
$126.0M
$455.8M
Q3 25
$219.0M
$606.2M
Q2 25
$249.0M
$547.9M
Q1 25
$73.0M
$-84.6M
Q4 24
$124.0M
$316.9M
Q3 24
$204.0M
$438.4M
Q2 24
$207.0M
$489.1M
Q1 24
$176.0M
$-54.4M
Free Cash Flow
CBT
CBT
IVZ
IVZ
Q4 25
$57.0M
$432.2M
Q3 25
$155.0M
$586.4M
Q2 25
$188.0M
$530.4M
Q1 25
$1.0M
$-108.0M
Q4 24
$47.0M
$309.9M
Q3 24
$112.0M
$410.0M
Q2 24
$155.0M
$462.4M
Q1 24
$133.0M
$-75.4M
FCF Margin
CBT
CBT
IVZ
IVZ
Q4 25
6.7%
25.5%
Q3 25
17.2%
35.7%
Q2 25
20.4%
35.0%
Q1 25
0.1%
-7.1%
Q4 24
4.9%
19.5%
Q3 24
11.2%
27.1%
Q2 24
15.3%
31.2%
Q1 24
13.1%
-5.1%
Capex Intensity
CBT
CBT
IVZ
IVZ
Q4 25
8.1%
1.4%
Q3 25
7.1%
1.2%
Q2 25
6.6%
1.2%
Q1 25
7.7%
1.5%
Q4 24
8.1%
0.4%
Q3 24
9.2%
1.9%
Q2 24
5.1%
1.8%
Q1 24
4.2%
1.4%
Cash Conversion
CBT
CBT
IVZ
IVZ
Q4 25
1.73×
Q3 25
5.09×
1.70×
Q2 25
2.47×
2.78×
Q1 25
0.78×
-0.49×
Q4 24
1.33×
1.51×
Q3 24
1.49×
7.97×
Q2 24
1.90×
3.70×
Q1 24
2.10×
-0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

Related Comparisons